A “glyco-optimized Herceptin®” with the potential to treat a broader patient group than existing therapy

Glycotope has exploited its proprietary technologies to develop a novel best-in-class second generation trastuzumab, an anti-HER2-receptor antibody with optimized and fully human glycosylation for the treatment of a variety of cancer indications.

The blockbuster trastuzumab has been approved for the treatment of HER2-positive breast cancer and HER2-positive stomach cancer.

Glycotope is actively seeking partners for TrasGEX®, our novel best-in-class anti-HER2-receptor antibody – a “glyco-optimized Herceptin” with the potential to treat a broader patient group than existing therapy.
Contact us
Pipeline

Utilizing the company’s unique technology platform, Glycotope has developed a mature pipeline of first-in-class and best-in-class biopharmaceuticals. Three oncology products are currently in advanced clinical development

Find out more

Key data

In a Phase I dose escalation study, single agent TrasGEX® was well tolerated and showed clinically meaningful tumor response and disease control.

Differentiation/mode of actions/specificity

TrasGEX® has antigen binding properties fully comparable to Herceptin® (trastuzumab) and in addition shows significantly improved antibody dependent cellular toxicity (ADCC), in particular among all allotypes of the FcγIIIa-receptor mediating the ADCC, which could mean a significantly improved therapeutic outcome for patients eligible for treatment with trastuzumab. Simultaneously, the fully human nature of GEX® host cell lines avoids the common immunogenic reactions against host-derived non-human components.